ESTRO 2023 - Abstract Book

S47

Saturday 13 May

ESTRO 2023

Conclusion SicAS highlights the need for National Association initiatives to support members’ scientific activities. National Societies could help by developing and supporting networks among all members, creating links among universities, hospitals, research institutes and industries, and providing guideline definitions and learning platforms enhancing the members’ involvement in scientific activities of the MPEs. The FutuRuS group will keep promoting and supporting such topics. Hopefully other National Associations of MP will join such a journey, identifying common barriers and figuring out solutions and collaboration possibilities. PD-0083 Analysis of the cost-effectiveness of proton beam therapy for unresectable pancreatic cancer Y. Hiroshima 1 , M. Kondo 2 , T. Sawada 3 , S. Hoshi 2 , R. Okubo 2 , T. Iizumi 3 , H. Numajiri 3 , T. Okumura 3 , H. Sakurai 3 1 University of Tsukuba, Department of Radiation Oncology & Proton Medical Research Center, Faculty of Medicine, Tsukuba, Japan; 2 University of Tsukuba, Department of Health Care Policy and Health Economics, Faculty of Medicine, Tsukuba, Japan; 3 University of Tsukuba, Department of Radiation Oncology & Proton Medical Research Center, Faculty of Medicine, Tsukuba, Japan Purpose or Objective Pancreatic cancer is one of the most common malignant tumors and has a poor prognosis. Recently, an increasing number of reports have used proton beam therapy (PBT) to treat unresectable, locally advanced pancreatic cancer (LAPC). However, the cost-effectiveness of PBT for pancreatic cancer has not been evaluated. This study aimed to determine the cost-effectiveness of PBT for LAPC as a replacement for conventional photon radiotherapy (RT). Materials and Methods We estimated the incremental cost-effectiveness ratio (ICER) of PBT as a replacement for three-dimensional conformal radiotherapy (3DCRT), a conventional photon RT, using clinical evidence in the literature and expense complemented by expert opinions. We used a decision tree and an economic and Markov model to illustrate the disease courses followed by LAPC patients. In the decision tree model, we assumed that some patients underwent chemotherapy after receiving PBT or 3DCRT. Effectiveness was estimated as quality-adjusted life years (QALY) using utility weights for the health state. The Markov cycle for each stage was set at one month, with the model programmed to cease when the cohort’s stage reached the 60th month. Social insurance fees were calculated as the costs. The stability of the ICER against the assumptions made was appraised using sensitivity analyses.

Results The effectiveness of PBT and 3DCRT was 1.67610615 and 0.97181271 QALY, respectively. The ICER was estimated to be ¥5,376,915 (US$46,756) per QALY. According to the suggested threshold for anti-cancer therapy from the Japanese authority of ¥7,500,000 (US$65,217) per QALY gain, such a replacement would be considered cost-effective. The one-way and probabilistic sensitivity analyses demonstrated stability of the base-case ICER.